Quarterly report pursuant to Section 13 or 15(d)

Consolidated Balance Sheets

v3.20.1
Consolidated Balance Sheets - USD ($)
Feb. 29, 2020
Nov. 30, 2019
Current Assets    
Cash and cash equivalents $ 8,415,639 $ 6,541,037
Marketable securities 959,001 904,053
Accounts receivable (net of allowance for doubtful accounts of $2,631,883 and $2,584,091, respectively) 5,766,684 6,097,331
Prepaid expenses 451,672 500,260
Inventory, current portion 1,102,824 1,084,533
Other current assets 199,064 260,397
Total current assets 16,894,884 15,387,611
Property and Equipment-net 1,774,587 1,846,467
Other Assets    
Intangible assets, net 1,232,338 1,249,254
Inventory, net of current portion 12,557,315 12,646,000
Goodwill 1,941,411 1,941,411
Deferred tax assets 9,079,994 9,079,994
Operating lease right-of-use asset 496,284  
Deposits and other assets, net 445,633 427,423
Total other assets 26,060,975 25,652,082
Total assets 44,730,446 42,886,160
Current Liabilities    
Accounts payable 1,381,242 1,369,111
Accrued expenses 2,713,807 2,085,180
Current portion of note payable 3,100,000 3,100,000
Current portion of operating lease liability 264,798  
Deferred revenue 8,610,304 8,875,138
Total current liabilities 16,070,151 15,429,429
Other Liabilities    
Deferred revenue, net of current portion 24,454,967 23,633,373
Contingent consideration 3,443,645 3,495,057
Note payable, net of current portion and debt issuance costs 5,105,633 5,856,152
Operating lease long-term liability 231,677  
Long-term liability - revenue sharing agreements 1,425,000 1,425,000
Total other liabilities 34,660,922 34,409,582
Total liabilities 50,731,073 49,839,011
Commitments and contingencies (Note 10) 0 0
Stockholders' Deficit    
Preferred stock 0 0
Common stock ($.01 par value, 20,000,000 authorized; 13,633,638 issued and 7,545,613 outstanding as of February 29, 2020 and 13,598,909 issued and 7,510,884 outstanding as of November 30, 2019) 136,336 135,989
Additional paid-in capital 36,183,738 35,918,827
Treasury stock, at cost (20,563,357) (20,563,357)
Accumulated deficit (21,757,344) (22,444,310)
Total stockholders' deficit (6,000,627) (6,952,851)
Total liabilities and stockholders' deficit 44,730,446 42,886,160
Series A Junior Participating Preferred Stock [Member]    
Stockholders' Deficit    
Preferred stock 0 0
Tianhe Stem Cell Biotechnologies Inc [Member]    
Other Assets    
Investment $ 308,000 $ 308,000